| | 2003 EMA Chart Review ¹ | 2005 CW Data | 2006 CW Data | 2007 Chart Review N=362 | 2009 CW Data ² | 2009 Chart Review N=739 | 2010 CW Data ³ | Benchmarks ⁴ |
|---------------------------------------|--|--------------------|--------------------|----------------------------------|------------------------------|----------------------------------|------------------------------|---|
| HAB HIV Core | Clinical Perfo | ormance Mea | sures for Ad | ult/Adolesce | nt Clients: H | RSA Group 1 | | |
| ARV Therapy for Pregnant Women* | N/A | N/A | N/A | 80.0% (N=5) | 100% | 58% (N=9) | 100% (N=16) | None available |
| CD4 T-Cell Count* | 79% every 6 mos. | N/A | 7.6% | 93.7% | 24.52% | 89% | 65.79% | EMA goal: 90% IHI Goal: 90% 2006 HQ Median: 62.5% |
| HAART* | N/A | N/A | N/A | 92.9% | 53.54% | 86% | 63.01% | EMA goal: 90% IHI Goal: 90% 2006 HQ Median: 100% |
| Medical visits* | N/A | 55% (3 in 1 yr) | 78% (3 in 1 yr) | 88.4% | 80.02% | 95% | 83.44% | EMA: 85% |
| PCP prophylaxis* | 97% | N/A | N/A | 81.4% | 24.52% | 92% | 24.95% | EMA goal: 95% IHI Goal: 95% 2006 HQ Median: 94.4% |

^{*} Also Atlanta EMA performance measure

1 2003 Chart review was based on PHS guidelines.

2 Run by Porter Butler, June 2010

3 Run by P. Butler, February 22, 2011. Includes the following agencies: AID Atlanta, AID Gwinnett, Cobb, Emory Midtown/Crawfrod Long, DeKalb, Fulton, Gray, Southern Crescent, St. Joe's.

4 Form FMA in disperse and 4/40 and HAR HIV Core Clinical Performance Measures for Additional Performance and Ald Alberta Reviews and 4/40 and HAR HIV Core Clinical Performance Measures for Additional Performance and Additional Performance Measures for Additional Performance and Additional Performance Measures for Additional Performance Measures for Additional Performance and Additional Performance Measures for Additional Performance Measures for Additional Performance and Additional Performance Measures for Additional Performance Measures

⁴ From EMA indicators approved 1/10 and HAB HIV Core Clinical Performance Measures for Adult/Adolescent Clients available at http://hab.hrsa.gov/special/coreclinical.htm

| | 2003 EMA Chart Review ⁵ | 2005 CW Data | 2006 CW Data | 2007 Chart Review N=362 | 2009 CW Data ⁶ | 2009 Chart Review N=739 | 2010 CW Data ⁷ | Benchmarks ⁸ |
|--|--|-------------------------|---|----------------------------------|------------------------------|----------------------------------|------------------------------|---|
| HAB HIV Core | Clinical Perfo | ormance Mea | sures for Ad | ult/Adolesce | nt Clients: Hi | RSA Group 2 | | |
| Adherence Assessment & Counseling* | 89% at 1 of last 2 visits | 24% (every 4 months) | 9.5% 3 or more in 1 yr ⁹ | 83.5% | 32.08% | 88% | 38.95% | EMA goal: 90% IHI Goal: 90% 2006 HQ Median: 55.7% |
| Cervical cancer screen* | 51% | 16% | 16% ¹⁰ | 62.0% | N/A | 11 | 20.81% | EMA goal: 80% IHI Goal: 90% 2006 HQ Median: 70.8% |
| Hepatitis B vaccination | 82% | N/A | N/A | N/A | 16.87% | 80% | 9.84% | HOPS 17% CDC 45% |
| Hepatitis C screening | 62% | N/A | 30% ¹² | 95.3% | 65.25% | 100% | 65.17% | EMA goal: 95% IHI Goal: 95% 2006 HQ Median: 90.9% |
| HIV Risk Counseling* | 77% ¹³ | N/A | N/A | 79.0% | 91.24% | 93% | 97.35% | EMA goal: 85% |
| Lipid Screening | 98% | N/A | N/A | N/A | 13.32% | 84% | 17.37% | 2006 HQ Median: 84.7% |

^{*} Also Atlanta EMA performance measure 5 2003 Chart review was based on PHS guidelines.

⁶ Run by Porter Butler, June 2010

⁷ Run by P. Butler, February 22, 2011. Includes the following agencies: AID Atlanta, AID Gwinnett, Cobb, Emory Midtown/Crawfrod Long, DeKalb, Fulton, Gray, Southern Crescent, St. Joe's.

⁸ From EMA indicators approved 1/10 and HAB HIV Core Clinical Performance Measures for Adult/Adolescent Clients available at http://hab.hrsa.gov/special/coreclinical.htm

9 Please note that ART_dummy created and selected for those coded as Yes (N=2056) 18% of these had at least one treatment adherence visit.

¹⁰ Selected for women 18 years or over where Pap did not equal N/A (N=1831). Data is missing for 74% of these women.

¹¹ Investigating data anomaly. Resolution by time of final report.

¹² Selected new clients only with enrollment year in 2006 (N=1357). Ran frequency on HepCTest only. No Hep A test data available. 24% missing, 36% no, 10% unknown.

¹³ Assessment only

| | 2003 EMA Chart Review ⁵ | 2005 CW Data | 2006 CW Data | 2007 Chart Review N=362 | 2009 CW Data ⁶ | 2009 Chart Review N=739 | 2010 CW Data ⁷ | Benchmarks ⁸ |
|---------------------|--|--------------------|----------------------|----------------------------------|------------------------------|----------------------------------|------------------------------|---|
| HAB HIV Core | Clinical Perfo | rmance Mea | sures for Adı | ult/Adolesce | nt Clients: Hi | RSA Group 2 | | |
| Oral exam* | N/A | N/A | N/A | 27.6% | 19.15% | 40% | 26.11% | EMA goal: 50% IHI Goal: 75% 2006 HQ Median: 39.4% |
| Syphilis screening* | 62% (at enrollment) | N/A | N/A | 80.1% | 71.85% | 81% | 68.04% | EMA goal: 90% IHI Goal: 90% 2006 HQ Median: 80% |
| TB screening* | 89% (past year) | 24% (past year) | 23%14 (past year) | 88.9% | 50.26% | 97% | 79.37% | EMA: 100% 2006 HQ Median: 56.2% |

| | 2003 EMA Chart Review ¹⁵ | 2005 CW Data | 2006 CW Data | 2007 Chart Review N=362 | 2009 CW Data ¹⁶ | 2009 Chart Review N=739 | 2010 CW Data ¹⁷ | Benchmarks ¹⁸ |
|---------------------|---|-----------------|-------------------|----------------------------------|-------------------------------|----------------------------------|-------------------------------|--------------------------|
| HAB HIV Core | Clinical Perfo | rmance Mea | sures for Ad | ult/Adolesce | nt Clients: HF | RSA Group 3 | | |
| Chlamydia screening | 12% (annually for 2 years) | N/A | N/A | 55.8% | N/A | 68% | 46.33% | None available |
| Gonorrhea screening | 13% (annually for 2 years) | 5% | 14% ¹⁹ | 56.4% | N/A | 69% | 46.21% | None available |

When controlling for client refusal and medical indication (N=6700), 25% of clients received PPD.

* Also Atlanta EMA performance measure

15 2003 Chart review was based on PHS guidelines.

16 Run by Porter Butler, June 2010

17 Run by P. Butler, February 22, 2011. Includes the following agencies: AID Atlanta, AID Gwinnett, Cobb, Emory Midtown/Crawfrod Long, DeKalb, Fulton, Gray, Southern Crescent, St. Joe's.

¹⁸ From EMA indicators approved 1/10 and HAB HIV Core Clinical Performance Measures for Adult/Adolescent Clients available at http://hab.hrsa.gov/special/coreclinical.htm

19 Selected new clients only with enrollment year in 2006 (N=1357). Ran frequency on STItest, so really shows who had STI test during enrollment year.

^{24%} missing, 40% no, 10% unknown.

| | 2003 EMA Chart Review ¹⁵ | 2005 CW Data | 2006 CW Data | 2007 Chart Review N=362 | 2009 CW Data ¹⁶ | 2009 Chart Review N=739 | 2010 CW Data ¹⁷ | Benchmarks ¹⁸ |
|--|---|-----------------|-----------------|----------------------------------|-------------------------------|----------------------------------|-------------------------------|--|
| HAB HIV Core | Clinical Perfo | rmance Mea | sures for Ad | ult/Adolesce | nt Clients: Hl | RSA Group 3 | | |
| Hepatitis B screening | 88% | N/A | N/A | 90.6% | N/A | 99% | 53.69% | None available |
| Hepatitis/HIV Alcohol Counseling | N/A | N/A | N/A | 53.2% | N/A | 47% | N/A | None available |
| Influenza vaccination | 77% | N/A | N/A | N/A | N/A | 63% | 17.61% | None available |
| MAC prophylaxis | 99% | N/A | N/A | 69.6% | N/A | 77% | 27.54% | 2007 HQ Median: 84.6% |
| Mental health screening | 79% ²⁰ | N/A | N/A | N/A | 77.66% | 95% | 93.44% | 2007 HQ Median: 42% |
| Pneumococcal vaccination | 87% | N/A | N/A | N/A | N/A | 84% | 38.31% | 2007 HQ Median: 90.9% |
| Substance use screening | 71% ²¹ | N/A | N/A | N/A | 92.21% | 97% | 92.49% | IHI Goal: 90% 2007 HQ Median: 80.6% |
| Tobacco cessation counseling | N/A | N/A | N/A | N/A | N/A | 57% | N/A | 2007 HQ Median: 80.6% |
| Toxoplasma screening | 75% | N/A | N/A | N/A | N/A | 80% | 18.40% | 2007 HQ Median: 83.8% |

Within 3 months of first medical visit and within last year
 Within 3 months of first medical visit and within last year

| | 2003 EMA Chart Review ²² | 2005 CW Data | 2006 CW Data | 2007 Chart Review N=362 | 2009 CW Data ²³ | 2009 Chart Review N=739 | 2010 CW Data ²⁴ | Benchmarks ²⁵ |
|------------------------------------|---|-----------------|--|----------------------------------|-------------------------------|----------------------------------|-------------------------------|--------------------------|
| Atlanta EMA In | dicators | | | | | | | |
| Problem list | 99% | N/A | N/A | 88% | N/A | 98% | N/A | None available |
| Allergy documentation | 79% | N/A | N/A | 71% | N/A | 100% | N/A | None available |
| Viral load | 59% | N/A | 7% (2 or more in 1 yr); 5% (3 or more in 1 yr) | 47% | N/A | 11% | N/A | EMA goal: 90% |
| Chlamydia Baseline Screening | 12% | 5% | 72% | 74% | N/A | 32% | N/A | EMA goal: 100% |
| Gonorrhea Baseline Screening | 13% | N/A | 72% | 75% | N/A | 32% | N/A | EMA goal: 100% |
| Nutrition Screening | 39% | N/A | N/A | 66% | N/A | 68% | N/A | None available |
| HIV Confirmatory Test | 64% | N/A | N/A | 69% | N/A | 78% | N/A | None available |

^{*} Also Atlanta EMA performance measure
22 2003 Chart review was based on PHS guidelines.
23 Run by Porter Butler, June 2010
24 Run by P. Butler [insert date]
25 From EMA indicators approved 1/10 and HAB HIV Core Clinical Performance Measures for Adult/Adolescent Clients available at http://hab.hrsa.gov/special/coreclinical.htm